 |
For all your Quality Management and Continual Improvement Initiatives and Standards
|
| View previous topic :: View next topic |
| Author |
Message |
GaryW Site Admin

Joined: 14 Oct 2005 Posts: 83186 Location: Adelaide, Australia

|
Posted: Sat Mar 13, 2010 7:48 am Post subject: AstraZeneca Comments On FDA Joint Advisory Committee Meeting On Post-Marketing Safety Studies For The Use Of LABAs In Asthma |
|
|
On March 10-11, 2010, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) -- including the Pulmonary-Allergy Drugs and the Drug Safety and Risk Management Advisory Committees -- discussed the design of post-marketing safety studies for long-acting beta-agonist (LABA)-containing products in the U.S., including SYMBICORT® (budesonide/formoterol fumarate dihydrate)...
Read more...
Source: Pharma Industry / Biotech Industry News From Medical News Today
Latest Health News and Medical News posted throughout the day, every day. _________________ Regards,
Gary Wilkinson
Founder & Principal Consultant
SQR Consulting |
|
| Back to top |
|
 |
|
|
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum You cannot attach files in this forum You cannot download files in this forum
|
|
|
© 2005 SQR Consulting - All rights reserved
ABN : 60512166070
Powered by phpBB © 2001, 2005 phpBB Group
|